This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Taro Pharmaceutical (TARO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of 111.11% and 8.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 6.90% and 3.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -14.81% and 4.62%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
by Zacks Equity Research
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lannett (LCI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lannett (LCI) delivered earnings and revenue surprises of 8.70% and 10.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -11.68% and 11.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 0% and 66.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 34.44% and 93.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -2.56% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -21.21% and 23.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Implied Volatility Surging for Xeris (XERS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Xeris (XERS) stock based on the movements in the options market lately.
Will Xeris Biopharma (XERS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals (XERS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -32.26% and -11.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Xeris Pharmaceuticals (XERS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
Xeris Pharmaceuticals (XERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of 3.23% and 6.42%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Xeris Pharmaceuticals (XERS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -5.13% and -22.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?